Abstract
Heparan sulfate proteoglycans (HSPGs) are widely distributed in mammalian tissues and involved in a number of processes related to malignancy. They are composed of a core protein to which chains of the glycosaminoglycan, heparan sulfate (HS), are attached. The existence of various classes of core protein, in addition to highly polymorphic HS chains, creates a superfamily of macromolecules with considerable diversity of structure and function. HSPGs interact with many proteins including growth factors, chemokines and structural proteins of the extracellular matrix to influence cell growth, differentiation, and the cellular response to the environment. The recent identification of two inherited syndromes that are associated with an increased cancer risk, and caused by mutations in HSPG-related genes, has intensified interest in these molecules. This review describes our current understanding of HSPGs in cancer and highlights new possibilities for therapeutic control. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alexander CM, Reichsman F, Hinkes MT, Lincecum J, Becker KA, Cumberledge S and Bernfield M (2000) Syndecan-1 is required for Wnt-1-induced mammary tumorigenesis in mice. Nat Genet 25: 329–332
Arai T, Akiyama Y, Nagasaki H, Murase N, Okabe S, Ikeuchi T, Saito K, Iwai T and Yuasa Y (1999) EXTL3/EXTR1 alterations in colorectal cancer cell lines. Int J Oncol 15: 915–919
Aviezer D, Iozzo RV, Noonan DM and Yayon A (1997) Suppression of autocrine and paracrine functions of basic fibroblast growth factor by stable expression of perlecan antisense cDNA. Mol Cell Biol 17: 1938–1946
Bernfield M, Gotte M, Park PW, Reizes O, Fitzgerald ML, Lincecum J and Zako M (1999) Functions of cell surface heparan sulphate proteoglycans. Ann Rev Biochem 68: 719–777
Chang Z, Meyer K, Rapraeger A and Friedl A (2000) Differential ability of heparan sulfate proteoglycans to assemble the fibroblast growth factor receptor complex in situ. FASEB J 14: 137–144
Choi C, Cho S, Horikawa I, Berchuck A, Wang N, Cedrone E, Jhung SW, Lee JB, Kerr J, Chenevix-Trench G, Kim S, Barrett JC and Koi M (1997) Loss of heterozygosity at chromosome segment Xq25–26.1 in advanced human ovarian carcinomas. Genes Chromosomes Cancer 20: 234–242
Conejo JR, Kleeff J, Koliopanos A, Matsuda K, Zhu ZW, Goecke H, Bicheng N, Zimmermann A, Korc M, Friess H and Buchler MW (2000) Syndecan-1 expression is up-regulated in panceatic but not in other gastrointestinal cancers. Int J Cancer 88: 12–20
Dhodapkar MV, Abe E, Theus A, Lacy M, Langford JK, Barlogie B and Sanderson RD (1998) Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91: 2679–88
Esko J (1999) Genetic analysis of proteoglycan structure, function and assembly. In Cell Surface Proteoglycans in Signalling and Development, Lander A, Nakato H, Selleck SB, Turnbull JE, Coath C (ed) pp 35–40, HFSP: Strasbourg
Gallagher JT and Lyon M (2000) Heparan sulphate: Molecular structure and interactions with growth factors and morphogens. In: Proteoglycans: Structure, Biology and Molecular Interactions, (Ed. Iozzo RV) Marcel Dekker: New York
Gonzalez AD, Kaya M, Shi W, Song H, Testa JR, Penn LZ and Filmus J (1998) OCI-5/GPC3, a glypican encoded by a gene that is mutated in the Simpson-Golabi-Behmel overgrowth syndrome, induces apoptosis in a cell line-specific manner. J Cell Biol 141: 1407–1414
Hecht JT, Hogue D, Strong LC, Hansen MF, Blanton SH and Wagner M (1995) Hereditary multiple exostosis and chondrosarcoma: linkage to chromosome 11 and loss of heterozygosity for EXT-linked markers on chromosomes 11 and 8. Am J Hum Genet 56: 1125–1131
Hennekam RCM (1991) Hereditary multiple exostosis. J Med Genet 28: 262–266
Hirabayashi K, Numa F, Suminami Y, Murakami A, Murakami T and Kato H (1998) Altered proliferative and metastatic potential associated with increased expression of syndecan 1. Tumour Biol 19: 454–463
Inki P and Jalkanen M (1996) The role of syndecan-1 in malignancies. Ann Med 28: 63–67
Jayson GC, Lyon M, Paraskeva C, Turnbull JE, Deakin JA and Gallagher JT (1998) Heparan sulfate undergoes specific structural changes during the progression from human colon adenoma to carcinoma in vitro. J Biol Chem 273: 51–7
Kitagawa H, Shimakawa H and Sugahara K (1999) The tumor suppressor EXT-like gene EXTL2 encodes an α1, 4-N-Acetylhexosaminyltransferase that transfers N-acetylgalactosamine and N-Acetylglucosamine to the common glycosaminoglycan-protein linkage region. J Biol Chem 274: 13933–13937
Kleef J, Ishiwata T, Kumbasar A, Friess H, Buchler MW, Lander AD and Korc M (1998) The cell-surface heparan sulphate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest 102: 1662–1673
Kumar-Singh S, Jacobs W, Dhaene K, Weyn B, Bogers J, Weyler J and Van Marck E (1998) Syndecan-1 expression in malignant mesothelioma: corrlelation with cell differentiation, WT1 expression, and clinical outcome. J Pathol 186: 300–305
Lin H, Huber R, Schlessinger D and Morin PJ (1999) Frequent silencing of the GPC3 gene in ovarian cancer cell lines. Cancer Res 59: 807–810
Lind T, Tufaro F, McCormick C, Lindahl U and Lidholt K (1998) The putative tumor suppressors EXT1 and EXT2 are glycosyltransferases required for the biosynthesis of heparan sulfate. J Biol Chem 273: 26265–26268
Lindahl U, Kusche-Gullberg M and Kjellen L (1998) Regulated diversity of heparan sulfate. J Biol Chem 273: 24979–82
Matsumoto A, Ono M, Fujimoto Y, Gallo L, Bernfield M and Kohgo Y (1997) Reduced expression of Syndecan 1 in human hepatocellular carcinoma with high metastatic potential. Int J Cancer 74: 482–491
McCormick C, Leduc Y, Martindale D, Mattison K, Esford LE, Dyer AP and Tufaro F (1998) The putative tumour suppressor EXT1 alters the expression of cell-surface heparan sulfate. Nat Genet 19: 158–161
McKenzie E, Tyson K, Stamps A, Smith P, Turner P, Barry R, Hircock M, Patel S, Barry E, Stubberfield C, Terrett J and Page M (2000) Cloning and expression profiling of Hpa2, a novel mammalian heparanase family member. Biochem Biophys Res Commun 276: 1170–1177
Merry CL, Lyon M, Deakin JA, Hopwood JJ and Gallagher JT (1999) Highly-sensitive sequencing of the sulphated domains of heparan sulphate. J Biol Chem 274: 18455–18462
Murthy SS, Shen T, De Rienzo A, Lee W-C, Ferriola PC, Jhanwar SC, Mossman BT, Filmus J and Testa JR (2000) Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 19: 410–416
Nackaerts K, Verbeken E, Deneffe G, Vanderschueren B, Demedts M and David G (1997) Heparan sulphate proteoglycan expression in human lung cells. Int J Cancer 74: 335–345
Paine-Saunders S, Viviano BL, Zupich J, Skarnes WC and Saunders S (2000) Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol 225: 179–187
Pilia G, Hughes-Benzie RM, MacKenzie A, Baybayan P, Chen EY, Huber R, Neri G, Cao A, Forabosco A and Schlessinger D (1996) Mutations in GPC3, a glypican gene, cause the Simpson-Golabi -Behmel overgrowth syndrome. Nat Genet 12: 241–247
Pye DA, Vives RR, Turnbull JT, Hyde P and Gallagher JT (1998) Heparan sulfate oligosaccharides require 6-O-sulfation for promotion of basic fibroblast growth factor mitogenic activity. J Biol Chem 273: 22936–22942
Raskind WH, Conrad EU, Chansky H and Matsushita M (1995) Loss of heterozygosity in chondrosarcomas for markers linked to hereditary multiple exostoses loci on chromosomes 8 and 11. Am J Hum Genet 56: 1132–1139
Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A and Borset M (2000) Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood 95: 388–92
Selleck SB (2000) Proteoglycans and pattern formation – Sugar biochemistry meets developmental genetics. Trends Genet 16: 206–212
Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA and Iozzo RV (1998) Antisense targetting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 102: 1599–1608
Stanley MJ, Stanley MW, Sanderson RD and Zera R (1999) Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am J Clin Pathol 112: 377–383
Stickens D, Brown D and Evans G (2000) EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis. Dev Dyn 218: 452–464
Van Kuppevelt TH, Dennissen MABA, van Venrooij WJ, Hoet RMA and Veerkamp JH (1998) Generation and application of type-specific anti-heparan sulfate antibodies using phage display technology. J Biol Chem 273: 12960–12966
Veugelers M, Cat BD, Muyldermans SY, Reekmans G, Delande N, Frints S, Legine E, Fryns JP, Schrander-Stumpel C, Weidle B, Magdalena N and David G (2000) Mutational analysis of the GPC3/GPC4 glypican gene cluster on Xq26 in patients with Simpson-Golabi-Behmel syndrome: identification of loss-of-function mutations in the GPC3 gene. Hum Mol Genet 9: 1321–8
Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Spector L and Pecker I (1999) Mammalian heparanse: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5: 793–802
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Blackhall, F., Merry, C., Davies, E. et al. Heparan sulfate proteoglycans and cancer. Br J Cancer 85, 1094–1098 (2001). https://doi.org/10.1054/bjoc.2001.2054
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.2054
Keywords
This article is cited by
-
High sensitivity analysis of nanogram quantities of glycosaminoglycans using ToF-SIMS
Communications Chemistry (2021)
-
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma
Journal of Translational Medicine (2020)
-
Changes in heparan sulfate sulfotransferases and cell-surface heparan sulfate during SKM-1 cells granulocytic differentiation and A549 cells epithelial-mesenchymal transition
Glycoconjugate Journal (2020)
-
Tumor matrix remodeling and novel immunotherapies: the promise of matrix-derived immune biomarkers
Journal for ImmunoTherapy of Cancer (2018)
-
Glycosaminoglycans are involved in bacterial adherence to lung cells
BMC Infectious Diseases (2017)